Rimegepant and chemo as first treatment for metastatic pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug, rimegepant, combined with standard chemotherapy (AG) as a first treatment for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pancreatic cancer that has spread to other parts of the body (metastatic) and cannot be removed by surgery.
- You have not received any prior treatment for your pancreatic cancer (like chemotherapy, radiation, or experimental drugs) except for surgery.
- You are in generally good health, able to do normal daily activities (ECOG 0 or 1), and your doctor expects you to live at least 3 months.
- Your blood work shows adequate organ function (normal blood cell counts, liver and kidney tests) and you are not pregnant or breastfeeding.
- You do not have other cancers, active infections, or serious health problems that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new combination of drugs (chiauranib, a PD-1 inhibitor, and two chemotherapy drugs) for people with a specific type of advanced pancreatic cancer who have not had prior treatment. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for people with pancreatic cancer that has not spread to the brain. It aims to see if this combination works better than standard treatments.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.